Description

The biologics market in China in terms of revenue is set to grow by US$ 109 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 19.3% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for biologics. The China biologics market is segmented on the basis of type. By type, it is categorized into blood products, mAb (monoclonal antibody), recombinant therapeutic proteins, vaccines, and others. The recombinant therapeutic proteins segment held the largest market share of 26.4% in 2020.

The report has profiled some of the key players of the market such as Beijing SL Pharmaceutical Co. Ltd., Fosun Group, Novo Nordisk A/S, Qilu Pharmaceutical Co. Ltd., Roche Holding AG, Sihuan Pharmaceutical Holdings Group Ltd..

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the biologics market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Type: blood products, mAb (monoclonal antibody), recombinant therapeutic proteins, vaccines, and others
Years Considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders

Get a comprehensive picture of the China biologics market
Pinpoint growth sectors and trends for investment
Understand what the future of the biologics market in China looks like
Identify the competitive landscape and window of opportunity

Table of Contents

1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Biologics Market by Type
4.1 Blood Products
4.2 Mab (Monoclonal Antibody)
4.3 Recombinant Therapeutic Proteins
4.4 Vaccines
4.5 Others
5. Company Profiles
5.1 Beijing SL Pharmaceutical Co., Ltd.
5.2 Fosun Group
5.3 Novo Nordisk A/S
5.4 Qilu Pharmaceutical Co., Ltd.
5.5 Roche Holding AG
5.6 Sihuan Pharmaceutical Holdings Group Ltd.
6. Appendix
6.1 About StrategyHelix
6.2 Disclaimer